

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA**

_____)	
DEPOMED, INC.,)	
)	
Plaintiff,)	
)	
v.)	Civil Action No. 12-cv-1592 (KBJ)
)	
UNITED STATES DEPARTMENT OF)	
HEALTH AND HUMAN SERVICES,)	
<i>et al.</i> ,)	
)	
Defendants.)	
_____)	

ORDER

For the reasons set forth in the accompanying Memorandum Opinion, it is hereby **ORDERED** that Plaintiff’s [20] motion for summary judgment is **GRANTED**, and Defendants’ [22] motion to dismiss or, in the alternative, for summary judgment is **DENIED** and judgment is entered in favor of Plaintiff. It is

FURTHER ORDERED that the FDA shall recognize orphan-drug marketing exclusivity for Gralise, without requiring proof of clinical superiority or imposing any additional conditions on Depomed, for a period of seven years from the date the FDA approved Gralise for marketing. This is a final appealable order.

DATE: September 5, 2014

KetANJI Brown Jackson

 KETANJI BROWN JACKSON
 United States District Judge